For NSCLC patients with sensitive EGFR mutations, the application of EGFR-TKIs as a first- or second-line therapy did not result in a difference in OS (Mok et al., 2009; Rosell et al., 2012). This evidence concerns the gene EGFR and non-small cell lung carcinoma.